We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Rapid Olfactory Test Shows Potential as Screening Tool for COVID-19

By LabMedica International staff writers
Posted on 20 Jul 2021
A study that evaluated the feasibility of a novel, objective olfactory test as part of an initial screening for COVID-19 in adults with unknown disease status has concluded that olfactory dysfunction (OD) is one of the earliest and strongest predictors of COVID-19 infection, and thus is promising as a disease screening tool.

In the prospective, cross-sectional study, researchers at University of California, San Diego (La Jolla, CA, USA) enrolled healthy adults (aged ≥ 18 years) from a single college campus COVID-19 screening site. More...
Participants were screened for OD using a novel scent card (SAFER Diagnostics) followed immediately by polymerase chain reaction (PCR) testing for SARS-CoV-2 from nasopharyngeal swabs. The SAFER card contained a single scent in a scratch-and-sniff label that the participant identified from 8 answer options: lemon, grape, floral, blueberry, banana, mint, unsure, or no scent. Answers were processed electronically via a QR code. An incorrect choice was classified as OD. Participant demographics, medical history, COVID-19 symptoms, and subjective smell function on a binary and 10-point visual analog scale (VAS, with 0 indicating no sense of smell and 10 indicating normal sense of smell) were also collected.

A total of 163 participants were prospectively screened for OD using the scent card followed by SARS-CoV-2 PCR testing. Of those who tested PCR-positive for COVID-19, 75% (12 out of 16) failed olfactory screening compared with 4.8% (7 out of 147) among those testing PCR-negative for COVID-19. The sensitivity, specificity, positive predictive value, and negative predictive value of the scent card in detecting those with COVID-19 were 75.0%, 95.2%, 63.2%, and 97.2%, respectively. Including the symptom fatigue along with OD achieved 93.8% sensitivity and 89.8% specificity in disease screening. The addition of fever and cough did not further increase sensitivity.

While only 37.5% (6 out of 16) of COVID-19 test-positive participants reported subjective anosmia, 75% failed screening with the scent card. A failed scent card screen was the greatest predictor of COVID-19 positivity (odds ratio [OR], 80.24; 95% CI, 14.77-435.90) when compared with other symptoms including cough, fever, fatigue, and a history of COVID-19 exposure. Thus, the study demonstrated that a rapid psychophysical olfaction test is feasible as a screening tool for COVID-19.

Related Links:
University of California, San Diego


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.